After focusing on 29 long COVID patients who initially tested negative, researchers found that a majority — 93 percent — were women around the age of 43.
The study, which was published in the American Academy of Neurology’s Neurology Neuroimmunology & Neuroinflammation journal, tested patients for antibody and T cell responses and compared it to two proteins from the COVID-19 virus and found that “patients’ responses were mixed rather than all or nothing, suggesting that a comprehensive evaluation is necessary and that immunologic tests are not a one-size-fits-all for confirming prior exposure to the virus,” Igor Koralnik, MD, chief of neuroinfectious diseases and global neurology at Northwestern Medicine, who oversees the Neuro COVID-19 Clinic said in the release.
The findings, he noted, should be prioritized by post-COVID clinics to no longer require a positive test result to provide care to a patient who suspects they are experiencing long COVID-19 symptoms.
“Millions of people in the United States have been rejected by the medical establishment and stigmatized because they didn’t carry a definite diagnosis of COVID-19 when they presented with their long COVID symptoms,” Dr. Koralnik stated. “We hope those people feel vindicated by our study.”
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
